FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325442 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

354

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Hypertension

Interventions

DRUG: Oral treprostinil (UT-15C) sustained release tablets
DRUG: Placebo

Sponsor

United Therapeutics